Chieh-Hsin Lin1, Ching-Hua Lin2, Yue-Cune Chang3, Yu-Jhen Huang4, Po-Wei Chen5, Hui-Ting Yang6, Hsien-Yuan Lane7. 1. Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan; Center for General Education, Cheng Shiu University, Kaohsiung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. 2. Department of Adult Psychiatry, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan. 3. Department of Mathematics, Tamkang University, Taipei, Taiwan. 4. Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan. 5. Department of Psychiatry, Taichung Chin-Ho Hospital, Taichung, Taiwan. 6. Department of Nutrition, China Medical University, Taichung, Taiwan. 7. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan. Electronic address: hylane@gmail.com.
Abstract
BACKGROUND:Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response toclozapine. METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that had been stabilized withclozapine were allocated into three groups for 6 weeks' add-on treatment of 1 g/day sodium benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and Global Assessment of Functioning. Side effects and cognitive functions were also measured. RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group. CONCLUSIONS:Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant schizophrenia. Further studies are warranted to elucidate the optimal dose and treatment duration as well as the mechanisms of sodium benzoate for clozapine-resistant schizophrenia.
RCT Entities:
BACKGROUND:Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophreniapatients who had poor response to clozapine. METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that had been stabilized with clozapine were allocated into three groups for 6 weeks' add-on treatment of 1 g/day sodium benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and Global Assessment of Functioning. Side effects and cognitive functions were also measured. RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group. CONCLUSIONS:Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant schizophrenia. Further studies are warranted to elucidate the optimal dose and treatment duration as well as the mechanisms of sodium benzoate for clozapine-resistant schizophrenia.
Authors: J Alexander Bodkin; Michael J Coleman; Laura J Godfrey; Claudia M B Carvalho; Charity J Morgan; Raymond F Suckow; Thea Anderson; Dost Öngür; Marc J Kaufman; Kathryn E Lewandowski; Arthur J Siegel; Elliot Waldstreicher; Christopher M Grochowski; Daniel C Javitt; Dan Rujescu; Scott Hebbring; Richard Weinshilboum; Stephanie Burgos Rodriguez; Colette Kirchhoff; Timothy Visscher; Alexander Vuckovic; Allison Fialkowski; Shane McCarthy; Dheeraj Malhotra; Jonathan Sebat; Donald C Goff; James I Hudson; James R Lupski; Joseph T Coyle; Uwe Rudolph; Deborah L Levy Journal: Biol Psychiatry Date: 2019-05-09 Impact factor: 13.382
Authors: Lili Veronika Nagy; Zsolt Kristóf Bali; Gábor Kapus; Péter Pelsőczi; Bence Farkas; Balázs Lendvai; György Lévay; István Hernádi Journal: Int J Neuropsychopharmacol Date: 2021-05-18 Impact factor: 5.176